Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced the acceptance of an abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago from May 30 to June 3, 2025. The presentation will showcase clinical data from their ongoing Phase 1/2 trial of azenosertib, their WEE1 inhibitor, in combination with encorafenib and cetuximab for treating patients with metastatic BRAF V600E mutant colorectal cancer.
The poster presentation, titled 'Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib,' will be presented by Dr. Jeanne Tie on Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT. The data cutoff date for the presentation is April 4, 2025. The poster will be available on the Zentalis website under the 'Supporting Publications' tab in the 'Our Approach' section.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) ha annunciato l'accettazione di un abstract per una presentazione poster al 2025 ASCO Annual Meeting che si terrà a Chicago dal 30 maggio al 3 giugno 2025. La presentazione mostrerà i dati clinici del loro trial di Fase 1/2 in corso su azenosertib, un inibitore di WEE1, in combinazione con encorafenib e cetuximab per il trattamento di pazienti con carcinoma colorettale metastatico con mutazione BRAF V600E.
Il poster, intitolato 'Risultati dell'escalation di dose di Fase 1 dell'inibitore WEE1, azenosertib', sarà presentato dalla Dott.ssa Jeanne Tie sabato 31 maggio 2025, dalle 9:00 alle 12:00 CDT. La data di cutoff dei dati per la presentazione è il 4 aprile 2025. Il poster sarà disponibile sul sito di Zentalis nella sezione 'Supporting Publications' sotto la scheda 'Our Approach'.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) ha anunciado la aceptación de un resumen para la presentación de un póster en la Reunión Anual ASCO 2025 en Chicago, del 30 de mayo al 3 de junio de 2025. La presentación mostrará datos clínicos de su ensayo en curso de fase 1/2 con azenosertib, su inhibidor de WEE1, en combinación con encorafenib y cetuximab para tratar a pacientes con cáncer colorrectal metastásico con mutación BRAF V600E.
El póster, titulado 'Resultados de la escalada de dosis de fase 1 del inhibidor WEE1, azenosertib', será presentado por la Dra. Jeanne Tie el sábado 31 de mayo de 2025, de 9:00 a.m. a 12:00 p.m. CDT. La fecha límite de datos para la presentación es el 4 de abril de 2025. El póster estará disponible en el sitio web de Zentalis bajo la pestaña 'Supporting Publications' en la sección 'Our Approach'.
Zentalis Pharmaceuticals (NASDAQ: ZNTL)는 2025년 5월 30일부터 6월 3일까지 시카고에서 열리는 2025 ASCO 연례회의에서 포스터 발표 초록이 채택되었음을 발표했습니다. 이번 발표에서는 진행 중인 1/2상 임상시험에서 WEE1 억제제인 azenosertib를 encorafenib 및 cetuximab과 병용하여 BRAF V600E 돌연변이 전이성 대장암 환자를 치료한 임상 데이터를 선보일 예정입니다.
'WEE1 억제제 azenosertib의 1상 용량 증량 결과'라는 제목의 포스터는 2025년 5월 31일 토요일 오전 9시부터 12시까지 CDT 시간에 Jeanne Tie 박사가 발표합니다. 발표를 위한 데이터 컷오프 날짜는 2025년 4월 4일입니다. 해당 포스터는 Zentalis 웹사이트의 'Our Approach' 섹션 내 'Supporting Publications' 탭에서 확인할 수 있습니다.
Zentalis Pharmaceuticals (NASDAQ : ZNTL) a annoncé l'acceptation d'un résumé pour une présentation par affiche lors du Congrès annuel ASCO 2025 à Chicago, du 30 mai au 3 juin 2025. La présentation mettra en avant les données cliniques de leur essai de phase 1/2 en cours sur azenosertib, leur inhibiteur de WEE1, en combinaison avec encorafenib et cetuximab pour le traitement des patients atteints d'un cancer colorectal métastatique avec mutation BRAF V600E.
L'affiche, intitulée « Résultats de l'escalade de dose en phase 1 de l'inhibiteur WEE1, azenosertib », sera présentée par le Dr Jeanne Tie le samedi 31 mai 2025, de 9h00 à 12h00 CDT. La date de coupure des données pour la présentation est le 4 avril 2025. L'affiche sera disponible sur le site web de Zentalis dans l'onglet « Supporting Publications » de la section « Our Approach ».
Zentalis Pharmaceuticals (NASDAQ: ZNTL) hat die Annahme eines Abstracts für eine Posterpräsentation auf dem 2025 ASCO Annual Meeting in Chicago vom 30. Mai bis 3. Juni 2025 bekanntgegeben. Die Präsentation wird klinische Daten aus ihrer laufenden Phase-1/2-Studie mit azenosertib, ihrem WEE1-Inhibitor, in Kombination mit Encorafenib und Cetuximab zur Behandlung von Patienten mit metastasiertem kolorektalem Krebs mit BRAF V600E-Mutation zeigen.
Das Poster mit dem Titel „Phase-1-Dosiseskalationsergebnisse des WEE1-Inhibitors azenosertib“ wird am Samstag, den 31. Mai 2025, von 9:00 bis 12:00 Uhr CDT von Dr. Jeanne Tie präsentiert. Der Datenstichtag für die Präsentation ist der 4. April 2025. Das Poster wird auf der Zentalis-Website unter dem Reiter „Supporting Publications“ im Bereich „Our Approach“ verfügbar sein.
- Potential first-in-class and best-in-class WEE1 inhibitor development
- Progress in Phase 1/2 clinical trial with data ready for presentation
- None.
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL.
The poster will include clinical data as of an April 4, 2025 data cutoff from the Company’s ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer.
Abstract and poster presentation details are below:
Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with previously treated BRAF V600E mutant metastatic colorectal cancer”
Abstract Number: 3551
Poster Session: Gastrointestinal Cancer – Colorectal and Anal
Poster Board: 372
Date/Time: Saturday, May 31, 2025, 9:00 a.m. - 12:00 p.m. CDT
Presenter: Dr. Jeanne Tie
The poster can be accessed through the “Supporting Publications” tab on the “Our Approach” section of the Zentalis website on the day of the presentation.
About Azenosertib
Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Haibo Wang - Chief Business Officer
Ron Moldaver - Investor Relations
ir@zentalis.com
FAQ
What clinical trial data will Zentalis (ZNTL) present at ASCO 2025?
When and where will Zentalis (ZNTL) present their ASCO 2025 poster?
What is the potential market position of Zentalis (ZNTL) azenosertib?
What is the target patient population for Zentalis (ZNTL) azenosertib trial?
